Nasdaq21d
Nexalin Technology, Inc. Launches Clinical Trial for HALO™ Clarity Device to Treat Mild Traumatic Brain Injury and PTSD at UCSD
Nexalin Technology announces the shipment of HALO™ Clarity devices to UCSD for a clinical trial on mTBI and PTSD treatment. Nexalin Technology, Inc. has announced that the University of ...
Nasdaq1mon
Nexalin Technology, Inc. Receives IRB Approval for UCSD Clinical Trials of HALO™ Clarity Headset in Treating mTBI and PTSD
The independent study, led by UCSD, will investigate the efficacy of the HALO device in treating mild traumatic brain injury and post-traumatic stress disorder, particularly in military personnel.
The National Law Review21d
Nexalin Technology Announces Initiation of Patient Recruitment for UCSD’s TBI & PTSD Clinical Study Following IRB Approval
HALO™ Clarity Devices Successfully Shipped for First Phase of Clinical Trials HOUSTON, TX, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or ...
Business Insider1mon
Nexalin Technology Announces UCSD IRB Approval for use of HALO™ Clarity in Clinical Trials for mTBI and PTSD Treatment
This study is being conducted independently by UCSD. Nexalin is providing the HALO devices for research purposes but is not sponsoring, directing, or controlling the study or its outcomes.